Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE

Trial Profile

Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; DT-poliovirus vaccine
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 03 Jul 2012 Status for the extension trial changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01546909).
    • 06 Jun 2012 Planned end date for the extension trial is Nov 2012 as reported by ClinicalTrials.gov (Extension trial: NCT01546909).
    • 06 Jun 2012 Trial status for the extension trial is recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01546909).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top